CTLA4 and Miyoshi myopathy: Indeed, a recent randomized trial evaluating the combination of anti-PD-1 and anti-CTLA4 as first-line immunotherapy supports a role for the PD-1/PD-L1 interaction as a clinically relevant immune regulatory mechanism in MM [10].